| | |
Radhieka Pandeya 01:15 AM | January 22,2009
Office of the drugs controller general of India issued warning letters asking for explanations, based on the audit findings
|
|
Radhieka Pandeya 10:07 PM | October 26,2008
Experts caution the country’s lack of expertise in testing should be factored in while giving approvals
|
|
Lison Joseph and Bhuma Shrivastava 10:32 PM | September 07,2008
At least six of the 20 drugs being investigated by the US FDA for potential adverse effects are being sold in India
|
|
Bhuma Shrivastava 12:01 AM | July 21,2008
DCGI also intends to initiate inspection of non-Indian plants to ensure the quality of drug raw materials being imported from other countries such as China
|
|
Bhuma Shrivastava 01:13 AM | May 19,2008
Current estimates of fake drugs put the prevalence between 0.5% and 30% of all the Rs34,000 crore-worth drugs sold in India
|
|
Jeetha D’Silva and C.H. Unnikrishnan 01:13 AM | February 25,2008
A US report associates higher cardiac risk with Sutent, a kidney cancer drug launched in India last month
|
|
C.H. Unnikrishnan 12:27 AM | December 19,2007
The court had stayed an order of DCGI that banned combination drug licences issued by state authorities
|
|
C.H. Unnikrishnan 12:23 AM | August 02,2007
Move will result in DCGI’s office pushing critical initiatives such as monitoring of human drug trials, survey on spurious drugs, elimination of drug combinations with questionable efficacy
|
|